Bristol-Myers Squibb Company
Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
Last updated:
Abstract:
Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
Status:
Application
Type:
Utility
Filling date:
20 Dec 2021
Issue date:
16 Jun 2022